IQVIA Holdings Inc.: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-07-05
Other years: 2026 vs 2025 · 2025 vs 2024
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

1
New Risks
2
Removed
7
Modified
54
Unchanged
🟢 New in Current Filing Increasing focus on environmental sustainability and social initiatives could increase our costs, and inaction could harm our reputation and adversely impact our financial results. 🔒
🔴 No Match in Current Filing Our business and operations have been and may in the future be adversely affected by the novel coronavirus (COVID-19) pandemic. 🔒
🟡 Modified We may be affected by healthcare reform and potential additional reforms, which may adversely impact the biopharmaceutical industry and reduce demand for our services or negatively impact our profitability. 🔒
🔴 No Match in Current Filing If we do not keep pace with rapid technological changes, our services may become less competitive or obsolete. 🔒
🟡 Modified The biopharmaceutical services industry is highly competitive and our business could be materially impacted if we do not compete effectively or rapidly adapt to technological change. 🔒
🟡 Modified Our Research & Development Solutions business could subject us to potential liability that may adversely affect our results of operations and financial condition. 🔒
🟡 Modified IT systems and Information 🔒
🟡 Modified Market Forces 🔒
🟡 Modified Outsourcing trends in the biopharmaceutical industry and changes in aggregate spending and research and development budgets could adversely affect our operating results and growth rate. 🔒
🟡 Modified Risks Relating to Our Industry 🔒
10 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →